diabetestalk.net

Www.medtronicdiabetes.com

Minimed® 530g System

Minimed® 530g System

Diabetes shouldn't prevent you from living the life you want. Playing in the majors. Taking the stage. Falling in love. MiniMed 530G system with SmartGuard™ technology helps you better control your glucose levels and even takes action for you when you need it – so you can be free to experience life's exceptional moments. Worn on your body, the pump delivers tiny drops of rapid-acting insulin to match your needs. Change your pump tubing only once every two to three days. Bolus Wizard® calculator makes it easier to calculate mealtime insulin and may avoid insulin stacking.1 Set temporary basal rates and patterns around your activities. Get readings every five minutes, right on your pump. Track your glucose levels throughout the day, including the effects of food or exercise. Get alerted when you’re trending high or low, so you can make adjustments – ahead of time. MiniMed 530G system is an insulin pump that’s fully integrated with a glucose sensor to give you advanced diabetes control. It’s the only diabetes management system with SmartGuard™ technology that takes action for you and is proven to reduce your risk of lows*. And by helping you keep your glucose levels stable long-term, MiniMed system can help lower both your A1C and your risk of nerve, eye and kidney problems.2,3,4 A good night’s sleep can mean starting your day refreshed, ready to live the life you want. But when you’re living with diabetes, a restful sleep can sometimes feel out of reach. In fact, up to 75 percent of severe hypoglycemia happens at night.5 SmartGuard technology users experience about half as many nighttime lows* than those using a pump and sensor alone 6. Our exclusive SmartGuard technology mimics some of the functions of a healthy pancreas to provide you with advanced pr Continue reading >>

Bomba De Insulina - Medtronic Diabetes Latino

Bomba De Insulina - Medtronic Diabetes Latino

Este sitio web est destinado nicamente a adultos. El contenido y toda la informacin incluida aqu tiene fines informativos exclusivamente y no pretende sustituir en modo alguno el consejo, diagnstico o tratamiento mdico profesional. Los casos de pacientes comentados son experiencias concretas de un paciente especfico. Las respuestas a un tratamiento pueden variar de un paciente a otro. Comente siempre con su mdico la informacin del diagnstico y del tratamiento y asegrese de entender y seguir escrupulosamente esa informacin. Los enlaces a los sitios de redes sociales se incluyen como un servicio para usted, sin que esto signifique que dichos sitios cuenten con el respaldo de Medtronic; no somos responsables del contenido de sitios web externos, de ningn comentario o respuesta enviados por usted u otra persona al sitio web o la red social. Al enviar contenidos a una red social, entiende y reconoce que esta informacin est disponible para el pblico y que Medtronic puede utilizar dicha informacin para fines promocionales internos y externos. Medtronic har todo lo posible por supervisar los contenidos enviados a las plataformas de redes sociales y se reserva el derecho de revisar, corregir o borrar comentarios si los considera inadecuados (ej. comentarios ofensivos, spam). 2014 Medtronic, Inc. Todos los derechos reservados. Este sitio web no podr ser reproducido o utilizado en parte o en su totalidad de ningn modo ni por ningn medio sin permiso de Medtronic, Inc. Veo es una marca comercial y BolusWizard, MiniLink y CareLink son marcas registradas de Medtronic MiniMed, Inc. Continue reading >>

Transforming Diabetes Care Together, For Greater Freedom And Better Health

Transforming Diabetes Care Together, For Greater Freedom And Better Health

About Us For more than 30 years, Medtronic has been helping people with diabetes. Medtronic is working with the global community to change the way people manage diabetes. Together, we will transform diabetes care by expanding access, integrating care and improving outcomes, so people with diabetes can enjoy greater freedom and better health. Under the leadership of Hooman Hakami, Executive Vice President and President of the Diabetes Group, Medtronic Diabetes operates three global business units to serve customers worldwide. ï‚· The Intensive Insulin Management Business Unit: This business unit serves the needs of those with type 1 diabetes and those who use intensive insulin regimens with type 2 diabetes. This business unit is our history and our heritage, and where we have offered a comprehensive approach to improve outcomes and care. We remain committed to innovation so that we can develop the artificial pancreas and close the loop. ï‚· The Non-Intensive Diabetes Therapies Business Unit: This business unit focuses on addressing the needs of patients with type 2 diabetes who do not use intensive insulin regimens and provides solutions along the diabetes care continuum. This team, working together with our partners, patients, providers, and payers, is focusing on developing products and solutions to improve clinical outcomes and reduce the burden of managing type 2 diabetes. ï‚· The Diabetes Service and Solutions Business Unit: This business unit optimizes clinical outcomes and enhances the patient experience with our therapies. We are focused on innovation in consumables, such as infusion sets and accessories, and in transforming how data is collected, analyzed and presented through our CareLink system. This team addresses broader needs, including patient Continue reading >>

Medtronic Diabetes Advocates Forum 2016 (#medtronicdaf)

Medtronic Diabetes Advocates Forum 2016 (#medtronicdaf)

Medtronic held its annual Diabetes Advocates Forum at its headquarters in Northridge, CA, hosting a group of ~20 advocates from the United States, Canada, and Latin America, including DiabetesMine editor Amy Tenderich. Amy reports: "We got an update on their Artificial Pancreas efforts with their next-gen 670G hybrid closed loop system on its way, following the finishing of its recent pivotal trial. Medtronic also talked about their new Type 2 diabetes business unit (aka Non Intensive Diabetes Therapies - NDT). We also spent some quality time interacting with their top executives about how Medtronic can best help the patient community succeed. We brainstormed advocacy ideas in breakout sessions." "The overall message from the company was that they want to evolve from being 'just a product vendor' (insulin pumps & CGM sensors) to being a force behind 'better diabetes outcomes.'" Our theme for today at the #MedtronicDAF is our vision to transform #diabetes care together. pic.twitter.com/9t5vRubJ4z DiabetesMine (@DiabetesMine) Thu, Apr 14 2016 19:00:50 Latin America DOC: Our peeps situated globally south of us here in the States were well represented. This was apparently a result of not being invited to the last MedT forum in 2014, an the Latin DOC group advocated that they be included. And Medtronic listened! From what we saw in the live Twitter-stream during the #MedtronicDAF , it seems our DOC friends were keeping us in the loop on discussion there while also raising their voices and sharing their opinions -- as you do. Showing threshold suspends going off across the country on Dec 25, 2015 #MedtronicDAF pic.twitter.com/79FSNbriNg Continue reading >>

How To Get To Medtronic Diabetes In San Antonio By Bus

How To Get To Medtronic Diabetes In San Antonio By Bus

How to get to Medtronic Diabetes in San Antonio by Bus Get directions from your current location Directions to Medtronic Diabetes from the top locations in San Antonio using Bus Click on a route to get updated schedules, live arrivals and step-by-step directions. Click on a route to get updated schedules Click on a route and see step by step directions on a map, line arrival times and updated line schedules. What are the closest stations to Medtronic Diabetes? The closest stations to Medtronic Diabetes are: Talvera Ridge At Nusstar Energy is 234 yards away, 3 min walk Talavera Ridge At Medtronics is 465 yards away, 6 min walk Talvera Ridge & Worth Pkwy is 933 yards away, 11 min walk Which Bus lines stop near Medtronic Diabetes? Supports over 1500 cities in 79+ countries worldwide! Add this badge to your website. Click to copy HTML Copy and paste the code below to your website (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; js = d.createElement(s); js.id = id; js.src = "fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'moovit-jsw')); (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; js = d.createElement(s); js.id = id; js.src = "fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'moovit-jsw')); Traveling to Medtronic Diabetes in San Antonio has never been so easy. Use Moovit to get detailed step by step directions as you travel from your current location or from a top attraction or any major public transit station. View detailed routes on a map, see bus and train schedules, arrival times, and service alerts so you know exactly how to get to Medtronic Diabetes. When traveling to Medtronic Diabetes use Moovit's Live Directions with Get Off Notifications to know exactly where and how far to walk, how long to wait for yo Continue reading >>

Insulin Pump - Medtronic Diabetes Sk

Insulin Pump - Medtronic Diabetes Sk

Obsah tejto webovej lokality a vetky uveden informcie slia len pre vau informciu a nemu v iadnom prpade nahradi odborn zdravotn poradenstvo, diagnostiku ani liebu. Prbehy pacientov s osobnmi sksenosami pecifickmi pre konkrtneho pacienta. Reakcie na liebu sa mu u jednotlivch pacientov li. Informcie o diagnze a liebe vdy prekonzultujte so svojm lekrom a uistite sa, e im rozumiete a dsledne ich dodriavate. Spolonos Medtronic odmieta zodpovednos za prpadn ujmy alebo kody priamo alebo nepriamo spsoben alebo dajne spsoben informciami uvedenmi na tejto webovej lokalite. Zoznamy indikci, kontraindikci, predbench opatren, vstrah a monch neiaducich inkov njdete v nvode na pouitie produktu. 2016 Medtronic International Trading Sarl. Vetky prva vyhraden. iadna as tejto webovej lokality sa nesmie reprodukova ani pouva v iadnej forme a iadnym spsobom bez shlasu spolonosti Medtronic International Trading Sarl. MiniMed, Bolus Wizard, SMARTGUARD, Guardian, Enlite a CareLink s ochrannmi znmkami spolonosti Medtronic, Inc. a jej dcrskych spolonost. Inc. CONTOUR je ochrann znmka spolonosti Bayer Healthcare LLC. Continue reading >>

College Diabetes Network Announces Medtronic Diabetes Corporate Membership

College Diabetes Network Announces Medtronic Diabetes Corporate Membership

Home / CDN News / College Diabetes Network Announces Medtronic Diabetes Corporate Membership College Diabetes Network Announces Medtronic Diabetes Corporate Membership Christina Roth, CEO & Founder College Diabetes Network College Diabetes Network Announces Medtronic Diabetes Corporate Membership BOSTON, MA (2016): The College Diabetes Network (CDN) is pleased to welcome Medtronic Diabetes as a Silver Level Corporate Member. CDN works with college students affected by diabetes and assists them in creating and running on-campus support networks, as well as provides access to information on how to live successfully with diabetes while at college and in young adulthood. The organization also works with college health centers, pediatric and adult endocrinologists, and parents to better support students in all aspects of their lives. CDN is changing the way people think about and accommodate the needs of young adults living with diabetes. Corporate Members serve an important role in helping CDN to fulfill our mission by providing the organization with the resources necessary to support and connect young adults, said Christina Roth, CDNs CEO and Founder. In addition, we strongly believe that the more interaction and understanding that our Corporate Members have of the young adult population, the better they will be able to meet their unique needs. Going off to university is a wonderful experience, filled with excitement, adventure and new opportunities to learn and grow. But being away from home for the first time, unpredictable schedules and other changes can be challenging for students with diabetes and the parents and caregivers who worry about them, said Louis Dias, chief patient officer for Medtronic Diabetes. As a Corporate Member, were thrilled to support CDNs outstan Continue reading >>

Medtronic Diabetes Therapy Associate Reviews

Medtronic Diabetes Therapy Associate Reviews

More Pros and Cons I worked at Medtronic as a contractor (More than a year) I worked at Medtronic full-time (More than a year) I worked at Medtronic full-time (More than a year) I have been working at Medtronic full-time (More than 3 years) I have been working at Medtronic full-time (More than 3 years) Acknowledge the responsibility level of each DTA compared to the DTC and accommodate the DTA salary as such to be within the same playing field of the DTC. Too many DTA's are lost because the effort that is put forth does not match the reward. Acknowledge that this environment is sales driven and don't look down on individuals that are motivated by financial gain. Remember that without financial gain the company … I have been working at Medtronic (More than a year) I have been working at Medtronic full-time (More than a year) Work-life balance leaned more on work. Got called in for mandatory team Saturdays only to find myself and another new employee coming in. Lack of communication upfront. Yes men/women do seem to accelerate into promotions, however most are a few lateral positions. Unless you plan to be a sales super or move into the pre-sales (consultant) position, don't expect much. Contractor company (Aerotek), provided misleading … I have been working at Medtronic full-time (More than a year) The work and life balance is hard to manage. I frequently come in on saturdays, not because I am required, but more so because I need to. My work load can be overwhelming. There hasn't ever been a slow week since I have worked here. We are always being asked to bring more to the table and bring more growth! The first year is a contract employment for most cases. No holiday, no paid sick days, terrible benefits. … I have been working at Medtronic full-time (More than a ye Continue reading >>

Medtronic Diabetes Advocates Forum 2016 Highlights

Medtronic Diabetes Advocates Forum 2016 Highlights

Medtronic has been a partner of Connected in Motion in Canada since our inception. In fact, Medtronic Canada helped the idea of Connected in Motion morph from some sketches Chloe Vances spiral notebook into a thing. They, along with Ascensia wait, what? Who? More on that soon), were the two companies that believe that CIM could be more than just an idea and put their networks, experiences, and their financial support into the very first Slipstream Weekend in 2009. Since then, Connected in Motion in Canada has continued to partner with Medtronic, bringing programs to life across the country, providing product trial opportunities (CIMers were some of the first people in the country to get to try the Enlite sensor when it first came out want your own opportunities to try out new-to-market (and some already existing) products join our Here in Canada, we are constantly hearing about the initiatives going on in the United States around Type 1 diabetes advocacy, the online community, and other Type 1diabetes themed get-togethers. Although there is much that we love about the Type 1 diabetes community in Canada (its generally focused, there isnt so much going on that you forget whats going on, our Type 1 community is tight-knit, etc.), we are often left out of much that happens south of the border even when the ideas, the technology, and the experiences are really not that different than our own. (Here in Canada, I feel like weve got really good at translating in all things into Canadian mg/dL into mmol/L, miles into kilometres, thresh suspend into low suspend and politely smiling and nodding when things are really not relevant or we just dont get it.) Needless to say, we were thrilled when we heard that the Canadians were being invited down to Medtronics annual Diabetes Advoc Continue reading >>

Medtronic's Diabetes Segment Generating Excitement

Medtronic's Diabetes Segment Generating Excitement

Medtronic's Diabetes Segment Generating Excitement Medtronic's Diabetes Group is the smallest, but fastest growing segment in the company's portfolio. Investors are excited about its prospects due to the 670G insulin pump. The 670G device is the first insulin pump for diabetes patients that is integrated with its sensors. This drastically reduces some of the drawbacks of using insulin pumps. The Diabetes Group segment is expected to grow significantly as Medtronic iterates on the 670G. Longer-term, the segment could potentially double in size as Medtronic becomes a larger diabetes player. Medtronic ( MDT ) is a pure-play medical device company. The company is a mid-single digit revenue grower driven by product segment innovation, international growth, and acquisitions. Profitability is further boosted by integration of their acquisitions and growth within their high-margin segments. They also generate strong free cash flow and aim to return 50% of that to investors. As a quick overview, Medtronic is split up into four segments: the Cardiac and Vascular Group (CVG), the Minimally Invasive Group (MITG), the Restorative Therapies Group (RTG), and the Diabetes Group (DG). CVG is the largest segment at 35% of sales. The MITG and RTG business are slower segments that have historically grown in the low-single digits. DG is the smallest, but fastest growing, segment and is arguably the most promising one among all of them. This is the segment I'll zoom in on in this article. For those who are unfamiliar, let's first talk about diabetes and survey the available treatments. But first, a disclaimer: I am no medical expert on diabetes, but hopefully I can give enough context and color on the basics for the purposes of this article. There's two types of diabetes: Type 1 and Type 2. Continue reading >>

Medtronic Diabetes Laying Off More Than 400 At Northridge Site

Medtronic Diabetes Laying Off More Than 400 At Northridge Site

M edtronic Diabetes is laying off more than 400 workers at its Northridge facility as the company consolidates and shifts its customer service operation to Texas, officials said Wednesday. A total of 464 positions will be eliminated by October 30, including about 300 customer service jobs being transferred to San Antonio, spokeswoman Amanda Sheldon said. Those call-center employees were offered the chance to relocate. About 1,800 employees will remain at the Devonshire Street campus, which is the headquarters for Medtronic Diabetes and where the company conducts research and manufactures insulin pumps and glucose monitoring systems. “To my knowledge we are committed to the division we have here as of right now,” Sheldon said. “We are restructuring the diabetes business to increase operating efficiencies.” Medtronic Inc., an international company based in Minneapolis, said in February it would eliminate about 2,100 jobs in response to market conditions. And in May 2009, it announced that San Antonio would be home to its new Diabetes Therapy Management and Education Center. At the time the company said it would staff the center with 1,400 workers over a five-year period. The company addressed its Northridge operation in that press release. “Medtronic continues to invest and grow its headquarters in Northridge and commitment to California employees remains strong,” it said. An analysis by the San Antonio Economic Development Foundation said the Medtronic facility will generate more than $750 million annually in economic benefits. Foundation President Mario Hernandez said his city attracted Medtronic through its business-friendly, low-cost reputation. “They are going to save 30 to 40 percent on all cost factors versus Los Angeles,” he said. “And (workers) Continue reading >>

Medtronic Announces Voluntary Recall Of Diabetes Infusion Sets

Medtronic Announces Voluntary Recall Of Diabetes Infusion Sets

Medtronic Announces Voluntary Recall of Diabetes Infusion Sets DUBLIN - September 11, 2017 - Medtronic plc (NYSE: MDT ) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors. The company determined, through recent field reports from patients and root cause analysis, that a component, the vent membrane, in the recalled infusion sets may be susceptible to being blocked by fluid during the process of priming/fill-tubing. This situation can lead to potential over-delivery of insulin shortly after an infusion set change, which may cause hypoglycemia. Currently manufactured infusion sets, available to patients since April 2017, include a design update of this component which the company believes reduces the risk of insulin over-delivery after an infusion set change. The company will work with patients to ensure recalled infusion sets with the discontinued component are returned and replaced with new infusion sets containing the updated component at no cost. Medtronic has contacted the U.S. Food and Drug Administration (FDA), along with other regulatory bodies around the world, to share information related to this issue. Medtronic will continue working directly with government and regulatory authorities on this global voluntary recall. "Our priority is to work with our patients to mitigate risk to patient safety. While we have shipped a significant number of the new and enhanced sets since April, we are committed to replacing recalled infusion sets for all patients," said Francine Kaufman, M.D., chief medical officer of the Diabe Continue reading >>

Medtronic Diabetes And Dexcom Rivalry To Heat Up

Medtronic Diabetes And Dexcom Rivalry To Heat Up

Johnson & Johnson announced Monday that FDA has approved the Animas Vibe insulin pump and continuous glucose monitoring system that features Dexcom's G4 Platinum sensing technology. This will likely heat up competition between Dexcom and another big name in the world of diabetes - Medtronic - with Dexcom getting the leg up, believes at least one analyst. But first, here are the features of the device. Johnson & Johnson and the company it acquired - Animas Corp. - is billing this device as the world's first and only integrated system featuring the Dexcom sensor. It may be the first pump to use the Dexcom sensor, but an integrated insulin pump and continuous glucose monitoring system is already available in the market from Medtronic. And neither of these two devices from Medtronic and J&J/Dexcom are truly integrated even though Medtronic claimed that its MiniMed 530g insulin pump with Enlite Sensor was a "first-generation artificial pancreas." In a truly integrated system, the pump would be smart enough to automatically adjust insulin delivery based on readings from the continuous glucose monitoring (CGM) system, wrote Gregory Chodaczek, an analyst with Sterne Agee, in a research note Monday - and do without requiring input from the patient. While we are not there yet, that will happen one day, Chodaczek believes. The Animas Vibe with DexCom's sensing technology, is however a "step in the right direction." The pump allows patients to view glucose readings on its screen without the need to carry the Dexcom receiver, Chodaczek wrote in a research note Monday. Here are other key features according to the news release: Dexcom CGM sensor technology is approved for up to seven days of continuous wear with one of the smallest introducer needles on the market. With Mean ARD (Abso Continue reading >>

Urgent Recall - Medtronic Minimed Infusion Sets

Urgent Recall - Medtronic Minimed Infusion Sets

Medtronic, in consultation with the Therapeutic Goods Administrations (TGA), has issued a global recall of some infusion sets used with Medtronic insulin pumps. This recall was initiated following recent reports of the potential over-delivery of insulin shortly after an infusion set change. Over-delivery of insulin can cause hypoglycaemia. To determine if you have any recalled infusion sets go to The website will prompt you to enter the REF and LOT numbers for all of the infusion sets in your possession. You will then be told which of the infusion sets are included in the recall, and which are not. If you have any recalled infusion sets, please complete the online form. To ensure that your replacement request is processed, make sure you click the SUBMIT button once your form is complete. Once the online form is submitted, replacement box/es of infusion sets will be sent by Medtronic directly to your nominated delivery address, free of charge. Please cut-out and retain the barcodes on your recalled infusion set boxes. These should be placed in the reply-paid envelope that will be included in the delivery of the replacement infusion sets. Send this envelope back to Medtronic but do not return the recalled infusion sets. You can dispose of your recalled infusion sets once you have returned the barcode to Medtronic. The following link contains more information on the recall, including important safety information about avoiding potential insulin over-delivery: Please do not use any of the recalled infusion sets. If necessary, please make use of your diabetes self-management back-up plan as agreed with your health professional until Medtronic are able to replace your recalled products. Medtronic has advised that replacement infusion sets are made with new and enhanced materi Continue reading >>

Medtronic Diabetes Device Pipeline Update From The J.p. Morgan Healthcare Conference

Medtronic Diabetes Device Pipeline Update From The J.p. Morgan Healthcare Conference

Medtronic Diabetes Device Pipeline Update from the J.P. Morgan Healthcare Conference Update (1/12/15):Medtronic Diabetes gave an update on their upcoming diabetes device pipeline at the J.P. Morgan Healthcare Conference. The MiniMed 640G is expected to be in the US by April 2016, and a hybrid closed loop system (the MiniMed 670G) is expected by April 2017! The MiniMed 640G uses a CGM reading to actually predict hypoglycemia before it occurs and thus suspend insulin delivery to avoid it. In Europe, the MiniMed 640G will launch by this April, and the MiniMed 670G isexpected to launch byApril 2018. Exciting to see automated insulin delivery moving forward into commercial products! Heaps of thanks to JDRF for its continued tremendous influence on this increasingly action-oriented field. Medtronic provided updates on several upcoming CGM and insulin delivery products at anearly Juneanalyst meeting. Though these meetings are really meant for investors, there is typically lots of valuable learning between and in the lines! Nearest term is the MiniMed 640G system, which we learned is actually already approved in the EU (!); this device uses a CGM reading to actually predict hypoglycemia before it occurs and thus suspend insulin delivery to avoid it. It then resumes insulin delivery once sensor glucose levels recover. The device is the next step forward from the MiniMed 530G/Enlite CGM ( read our test drive here ), which suspends insulin delivery once glucose levels reach a threshold for hypoglycemia. The MiniMed 640G system is expected to launch in Europe by April 2015, and a US trial of the device is starting very soon. You can see a sneak peak of the MiniMed 640G in the photo above, which is waterproof, will have a color screen, and feature a completely redesigned, simpler u Continue reading >>

More in diabetes